Tobacco, but not nicotine and flavor-less electronic cigarettes, induces ACE2 and immune dysregulation

Abby C. Lee 1,2†, Jaideep Chakladar 1,2†, Wei Tse Li 1,2†, Chengyu Chen1,2, Eric Y. Chang1, Jessica Wang-Rodriguez3, and Weg M. Ongkeko 1,2,*

1 Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of California San Diego, La Jolla, CA 92093, USA; acl008@ucsd.edu (A.L.); jchaklad@ucsd.edu (J.C.); wtl008@ucsd.edu (W.T.L.)
2 Research Service, VA San Diego Healthcare System San Diego, La Jolla, CA 92161, USA; acl008@ucsd.edu (A.L.); jchaklad@ucsd.edu (J.C.); wtl008@ucsd.edu (W.T.L.); rongkeko@health.ucsd.edu (W.M.O.)
3 Department of Radiology, Radiology Service, VA San Diego Healthcare System San Diego, University of California San Diego, La Jolla, CA 92093, USA; Eric.Chang2@va.gov

Abstract: COVID-19, caused by the virus SARS-CoV-2, has infected millions worldwide. This pandemic overlaps with the ongoing epidemics of cigarette smoking and electronic cigarette (e-cig) vaping, with over 1 billion smokers and vapers worldwide. However, there is scarce data relating COVID-19 risks and outcome with cigarette or e-cig use. In this study, we mined 3 independent RNA expression datasets from smokers and vapers to understand the potential relationship between vaping/smoking and the dysregulation of key genes and pathways related to COVID-19. We found that smoking, but not vaping, upregulates ACE2, the cellular receptor that SARS-CoV-2 requires for infection. Both smoking and use of nicotine and flavor-containing e-cig led to upregulations of pro-inflammatory cytokine production and expression of genes related to inflamasomes. Vaping flavor-less and nicotine-less e-cig, however, did not lead to significant cytokine dysregulation and inflammasome activation. Release of inflammasome products, such as IL-1β, and cytokine storms are hallmarks of COVID-19 infection, especially in severe cases. Therefore, our findings demonstrated that smoking or vaping, specifically use of flavored or nicotine-containing e-cigs, may critically exacerbate COVID-19-related inflammation or increase susceptibility to the disease. Further scientific and public health investigations should be undertaken to address these concerning links between COVID-19 and e-cig/smoking.

Keywords: Electronic cigarettes, vaping, COVID-19, SARS-CoV-2, ACE2, tobacco, inflammation, cytokines, immune response

1 Introduction

The current COVID-19 pandemic, caused by the virus SARS-CoV-2, has killed over 130,000 Americans in less than 4 months. The majority are over 65 years old, but many younger patients who have underlying medical conditions required admission to the intensive care unit. Current data indicate that patients who have cardiovascular and chronic respiratory conditions, including those caused by tobacco use, are at higher risk of developing severe COVID-19 symptoms and have significantly increased fatality [1]. There are increasing numbers of reports that smokers have worse clinical outcomes when infected with SARS-CoV-2 [2]. Information from China show that people who have cardiovascular and respiratory conditions caused by tobacco use are at higher risk of developing severe COVID-19 symptoms [2,3]. Furthermore, tobacco use is the most important risk-factor for chronic obstructive pulmonary disease (COPD) [4]. Finally, aside from lung damage, it is believed that smokers may be more vulnerable to SARS-CoV-2 because of an altered immune
response [5]. However, many studies reported otherwise. In a preprint, Farsalinos et al. concluded that smoking is not a risk factor for hospitalization due to COVID-19 [6]. One meta-analysis reported no association between smoking and severity of COVID-19 [7]. A French study even found that nicotine may protect against COVID-19 infection, prompting interests from the French Health Minister in studying whether nicotine patches could be used for COVID-19 treatment and prevention [8,9]. Unfortunately, all reports regarding tobacco and COVID-19 are from epidemiological data and only a few studies reported data. The lack of well-controlled laboratory experiments renders it extremely difficult to determine whether tobacco truly affects COVID-19 outcome and the mechanistic link between them. Furthermore, no peer-reviewed study has reported definitive data demonstrating or rejecting the hypothesis that COVID-19 incidence can be increased by tobacco smoking.

Electronic cigarettes (e-cigs) have dramatically increased in popularity in recent years, especially among the youth [10], so considerable attention has been directed to any potential link between e-cig and COVID-19 in recent months. E-cig has been shown to induce inflammation of human airways and may also increase susceptibility to pneumonia by increasing pneumococcal adherence to airway cells [11,12]. Notable damage to the lung epithelium could also be done by e-cig, resulting in increased airway hyperactivity and mucus production [12]. The detrimental effects of e-cig thus fueled speculation that e-cig may increase COVID-19 severity or incidence. However, virtually no study, both on the basic science level and epidemiological level, has linked COVID-19 to e-cig. Complicating research on e-cig’s effects on COVID-19 is the fact that e-cig can be vaped with or without nicotine and with or without flavorings. Flavors and nicotine in e-cig are frequently associated with more inflammation, epithelial barrier dysregulation, oxidative stress, and DNA damage than e-cig with only basic components [12,13].

A possible molecular mechanism for tobacco or e-cig to increase COVID-19 susceptibility is the upregulation of ACE2. For SARS-CoV-2, host recognition is carried out by the spike protein on the surface of the viral envelope. The spike protein binds the ACE2 receptor protein in human cells. After this, the spike protein can be cleaved by the serine protease TMPRSS2 [14]. SARS-CoV uses a similar mechanism for host recognition, after which, fusion of the viral envelope with membranes in the host cell will allow the virus entry into the cell [15]. This process is vital for the entry of SARS-CoV-2 into human host cells, and therefore plays an integral role in COVID-19 infection and disease progression. Cigarette smoke was found in some studies to increase ACE2 expression in lungs in mammals [16-18]. No study has reported on ACE2 expression’s relationship with e-cig use.

Another possible mechanism linking tobacco or cigarette smoking to COVID-19 is their propensity to increase lung inflammation. COVID-19 has a strong immunological component, and poor outcomes have recently been associated with cytokine storms and a hyperinflammatory immune system [19,20]. Tobacco is known to induce extensive immune dysregulation in smokers, and its influence has been found to lead to airway inflammation[21]. Although cigarette smoke has been associated with increased susceptibility to COVID-19[16], the effect of tobacco on the immune response to SARS-CoV-2 has not been studied. E-cig is also known to induce significant inflammation in the lungs, but the dysregulated immune landscape is different from that of tobacco [22,23]. Therefore, it is plausible that inflammation induced by tobacco or e-cig could exacerbate inflammation caused by SARS-CoV-2 infection, potentially triggering a lethal cytokine storm.

In this study, we directly investigated the two main hypotheses that might link COVID-19 to e-cig vaping and tobacco smoking, ACE2 upregulation and inflammation, by reanalysis of independent datasets with gene expression from e-cig vapers and tobacco smokers. We examined whether e-cig or tobacco upregulate ACE2, dysregulate immune cell population levels, affect cytokine levels, and regulate the activation of inflammasomes. Given that nicotine or flavorings present in the e-cig mixture are implicated in promoting lung damage, we examined one e-cig dataset where all participants only vaped e-cig with neither nicotine nor flavors and another e-cig dataset where participants only vaped e-cig with nicotine and were free to choose different flavors.

2. Results
2.1. Correlation between smoking/vaping and ACE2 expression in bronchial epithelial cells

To observe the relationship between smoking e-cigarettes and ACE2 expression, we used the following datasets: GSE138326 and GSE112073 [24,25]. The GSE138326 dataset, from Song et al., details gene expression in the bronchial epithelial cells of patients who smoked flavor-less and nicotine-less e-cig vs. those who did not. The GSE112073 dataset, from Corbett et al., details gene expression in bronchial cells of patients who smoked nicotine-containing e-cig of any flavor vs. those who smoked no e-cig. All patients in this dataset were former smokers. The Kruskal-Wallis analysis test was applied to determine differential expression of ACE2 between e-cig users and non-e-cig users for both of these datasets (p<0.05). In addition, whole transcriptome RNA sequencing data for normal bronchus and lung tissue samples of 49 lung squamous cell carcinoma (LUSC) patients from The Cancer Genome Atlas (TCGA) were downloaded. These patients are either current or former smokers. Former smokers were categorized into those who had quit less than 15 years from the date of sample collection and those who had quit more than 15 years. Differential expression analysis was conducted to compare gene expression in current smokers and former smokers (Kruskal-Wallis, p<0.05).

We found that smoking tobacco is associated with increased ACE2 expression in current smokers (p=0.0281). In addition, the difference in ACE2 expression between current smokers and former smokers who had quit for more than 15 years is more significant than that of current smokers and former smokers who had quit for less than 15 years (Fig 1A). This is not surprising as we expect that a longer duration since quitting smoking would be associated with a greater difference in ACE2 expression between current and former smokers. On the other hand, smoking e-cigarettes does not lead to increased ACE2 expression in either study (Fig 1B). These results suggest that tobacco smokers may be more vulnerable to SARS-CoV-2 infection than e-cigarette smokers if infection susceptibility is based upon ACE2 abundance.

Figure 1: ACE2 and general immune dysregulation analysis in tobacco and e-cig users. (A) Boxplots of ACE2 expression in current and former smokers, including those that have quit for less than and more than 15 years. (B) Boxplots of ACE2 expression in control and e-cigarette users, including patients who have never smoked tobacco and those who are former tobacco smokers. (C-E) Radar
plots comparing immune cell infiltration across smokers, e-cigarette users vaping nicotine-less, flavor-less e-cig, and vapers who used e-cigs containing nicotine and flavors. Greater immune cell infiltration is indicated by a value closer to zero and farther away from the center of the radar plot.

2.2. Correlation between smoking/vaping status and immune infiltration

Using the software tool CIBERSORTx [26], we deconvoluted the infiltrating lymphocyte population from bulk-tissue gene expression data (p<0.05). We also found that smoking tobacco is associated with increased immune cell infiltration (Fig 1C-E). Current tobacco smokers experienced an upregulation of memory B-cell and naive CD4 T-cell expression and downregulation of regulatory T-cell (Treg) expression, compared to former smokers (Figure 1C). Elevated levels of CD4 T-cells in current tobacco smokers could lead to higher levels of effector cytokines that contribute to lung inflammation, making tobacco smokers more susceptible to a more aggressive immune response and a possible cytokine storm. In fact, it was reported that CD4+ T-cells contribute effector inflammation cytokines after acute influenza infections in mice, even after no virus is detectable in blood [27]. Meanwhile, the downregulation of Tregs may deprive the immune system of inhibitory signals that can prevent cytokine storms from occurring [28]. Memory B cells upregulation is not known to be involved in a cytokine storm, but their expansion may be indicative of past infections and increased susceptibility to infection in smokers. Our data is consistent with existing literature, which reports that current smokers have higher percentages of memory B cells than former smokers [29]. On the other hand, e-cig use is not significantly associated with increased immune infiltration in either datasets (Figure 1D-E).

2.3. Correlation between smoking/vaping status and cytokine level dysregulation

We next examined whether cytokine levels are dysregulated in smokers or e-cig users. We found that current tobacco smokers display significant dysregulation of 18 cytokine genes, including 12 proinflammatory and 6 anti-inflammatory cytokines, compared to former tobacco smokers (Fig 2A,D,E). Of the proinflammatory cytokines, the following are of particular interest: CCL20, which has been associated with SARS-CoV, and IL-1B, CXCL1, CXCL2 and CXCL8, which are associated with COVID-19. CCL20 was highly expressed in healthy Peripheral Blood Mononuclear Cells (PBMCs) infected with SARS-CoV [30]. Given the similarities in the pathophysiology of SARS-CoV and COVID-19 infection, more research must be done to determine if CCL20 is upregulated in COVID-19 patients as well, thus contributing to a potential cytokine storm. COVID-19 infection of the upper and lower respiratory tract has been shown to release proinflammatory cytokines including IL-1B [31], and is also associated with increased levels of CXCL8, CXCL1, and CXCL2 [32], which are known to play roles in neutrophil recruitment [33,34]. CXCL8 has also been found to be positively correlated with the number of neutrophils recovered in ARDS patients [34]. Such excessive neutrophil recruitment during ARDS is associated with poorer clinical outcomes and greater disease severity [35,36]. Therefore, the upregulation of these cytokines in tobacco smokers may make them more vulnerable to excessive neutrophil migration, a more severe inflammatory response, and leave them more susceptible to cytokine storms. Of the anti-inflammatory cytokines, CXCL17 is upregulated in COVID-19 patients as well [32], but more research must be done to investigate its role in COVID-19 pathogenesis.
Figure 2: Cytokine-related gene expression. Bar plots of the fold change of significantly dysregulated cytokine genes in (A) Current vs former smokers; and control vs e-cig users that have used e-cig with (B) no flavors or nicotine or (C) with nicotine and/or flavors. Heat maps illustrating differences in cytokine gene expression between current smoker and former smokers that have either quit for (D) less than 15 years or (E) more than 15 years. Heat maps are split into quadrants based on current/former smokers and pro/anti-inflammatory cytokines. Red bar plots represent proinflammatory cytokines, and blue bar plots represent anti-inflammatory cytokines.

For the e-cig studies, we noticed that there are significant differences between vapers who used nicotine-less and flavor-less e-cig and vapers who used nicotine/flavor-containing e-cig. In nicotine-less and flavor-less e-cig users, we observed only one cytokine, IFNA8, being slightly dysregulated (Figure 2B). However, we observed the dysregulation of 6 pro-inflammatory cytokines, including CCL5, CCL3, and CXCL3, and 2 anti-inflammatory cytokines in those who used nicotine/flavor-containing e-cig (Figure 2C). CCL5 and CCL3 are both chemotactic cytokines that specifically attract T-cells and macrophages to the site of infection [37,38]. CCL5 is also critical to inhibiting macrophages from undergoing apoptosis after the activation of adaptive immunity, potentially leading to prolonged inflammation [38]. CXCL3 is a chemokine released by macrophages and may indicate increased airway inflammation [39]. In summary, our data suggest that use of nicotine or flavor-containing e-cig may lead to greater expression of inflammatory genes.
COVID-19 suggests the possibility that inflamasomes are activated.

When activated, inflamasomes cleave pro-IL-1B and pro-IL-18 into IL-1B and IL-18, allowing them to signal the presence of pathogens to nearby cells and initiate the inflammatory response [40]. The discovery that IL-1B is upregulated by both smoking and COVID-19 suggests the possibility that inflamasomes are activated.

### Table 1: Significantly dysregulated Cytokine-related genes.

| Gene | Geo2R | Kruskal-Wallis | P-value | logFC | P-value | logFC | Cohort |
|------|-------|----------------|---------|-------|---------|-------|--------|
| CCL20 | 0.0055 1418 | 0.1768 1939 | 0.0055 1418 | -0.3762 | 0.1768 1939 | -0.3762 | E-cig (with flavor/nicotine) vs Former Smokers |
| CCL17 | 0.0637 1988 | 0.0712 1927 | 0.0637 1988 | -0.1067 1949 | 0.0712 1927 | -0.1067 1949 | E-cig (with flavor/nicotine) vs Former Smokers |
| CXCL3 | 0.0975 1738 | 0.0872 1927 | 0.0975 1738 | -0.0958 1517 | 0.0872 1927 | -0.0958 1517 | E-cig (with flavor/nicotine) vs None |
| CXCL8 | 0.0398 0202 | 0.1098 1471 | 0.0398 0202 | -0.1098 1471 | 0.1098 1471 | -0.1098 1471 | E-cig (with flavor/nicotine) vs Former Smokers |
| IL18 | 0.0102 0604 | 0.1970 3496 | 0.0102 0604 | -0.1970 3496 | 0.1970 3496 | -0.1970 3496 | E-cig (with flavor/nicotine) vs Former Smokers |

#### 2.4. Investigation of inflammasome activation in e-cig and tobacco users

The upregulation of a significant number of inflammatory cytokines in smokers and nicotine/flavor-containing e-cig users and the association of smoking with IL-1B prompted us to examine inflammasome activation in smokers and e-cig users. Inflamasomes are large protein structures primarily located in macrophages that respond to inflammatory signals, namely molecular patterns from pathogens. When activated, inflamasomes cleave pro-IL-1B and pro-IL-18 into IL-1B and IL-18, allowing them to signal the presence of pathogens to nearby cells and initiate the inflammatory response [40]. The discovery that IL-1B is upregulated by both smoking and COVID-19 suggests the possibility that inflamasomes are activated.
We discovered that many key inflammasome genes and regulators besides IL-1β were upregulated in smokers vs. former smokers, including CXCL1 and CXCL2 (Figure 3). These genes are all upregulated in smokers vs. former smokers. Both CXCL1 and CXCL2 promote the activation of inflammasomes [41,42]. In the e-cigarette studies, we found that flavor-less and nicotine-less e-cigarette users showed no markers of inflammasome activation (Figure 3). However, users of nicotine/flavor-containing e-cigarette also exhibited highly significant upregulation of inflammasome-related genes, including NOD2, CCL5, and ASC (also known as PYCARD) (Figure 3). ASC is one of the 3 main components of inflammasomes. NOD2 can directly bind to NLRP1 inflammasomes to upregulate IL-1β release [43]. CCL5 expression may be induced by inflammasome activation, as IL-1β has been shown to induce CCL5 expression in lower airway cells [44]. Our data thus suggest that smoking and nicotine or flavor-containing e-cigarette, but not nicotine/flavor-less e-cigarette, could upregulate inflammasomes and potentially exacerbate COVID-19-induced inflammation.

Table 2: Significantly dysregulated Inflammasome-related gene expression

| Gene | Geo2R P-value | logFC | Kruskal-Wallis P-value | logFC | Cohort |
|------|---------------|-------|-----------------------|-------|--------|
| CCL5 | 0.85415       | 0.27319 | 0.00959 | 0.097886 | E-cig(without flavor/nicotine) vs None |
|      | 0.049094      | 0.032858 | 0.0421 | 0.07011 | E-cig (with flavor/nicotine) vs Former Smokers |
|      | 0.62266       | 0.241121 | 0.016747 | 0.000846 | Current vs Former Tobacco Smokers |
| CXCL1 | 0.274418     | 0.395149 | 0.00718 | 1.55367 | E-cig(without flavor/nicotine) vs None |
|      | 0.802924      | 0.429555 | 0.004948 | 0.11389 | Current vs Former Tobacco Smokers |
| CXCL2 | 0.359389     | 0.143227 | 0.003556 | 0.008202 | E-cig(without flavor/nicotine) vs None |
|      | 0.999722      | 0.000195 | 0.002349 | 0.158417 | E-cig(without flavor/nicotine) vs None |
|      | 0.183386      | 0.056236 | 0.013534 | 0.07004 | E-cig (with flavor/nicotine) vs Former Smokers |
| NLRP3 | 0.317834     | 0.459914 | 0.001984 | 0.002313 | E-cig(without flavor/nicotine) vs None |
|      | 0.207633      | 0.041556 | 0.014107 | 0.158417 | E-cig (with flavor/nicotine) vs Former Smokers |
|      | 0.659102      | 0.721277 | 0.00158 | 0.11389 | E-cig(without flavor/nicotine) vs None |
|      | 0.048781      | 0.187701 | 0.017268 | 0.010456 | E-cig (with flavor/nicotine) vs Former Smokers |
| PYCARD | 0.004566     | 0.272032 | 0.017268 | 0.11389 | Current vs Former Tobacco Smokers |
|      | 0.004566      | 0.272032 | 0.017268 | 0.11389 | Current vs Former Tobacco Smokers |
Figure 3: Boxplots of significant correlations of e-cig or tobacco use with upregulation of inflammasome genes (Kruskal Wallis, \( p < 0.05 \)). A schematic linking the genes upregulated with their function within inflammasome pathways is shown.

3. Discussion

The current COVID-19 pandemic intersects with the ongoing epidemic of tobacco smoking and e-cig vaping in the U.S. and across the globe. Tobacco usage has been declining gradually over the years. 42.3% of U.S. adults smoked cigarettes in 1965, but only 13.7% do so in 2018, according to data from the National Health Interview Survey (NHIS). The smoking rate among young adults have also fallen similarly, with 7% of young adults smoking in 2018 [44]. Although these trends are encouraging, it does not mask the fact that millions of Americans are still active smokers. The many detrimental effects tobacco can have on the lungs and other organs have made tobacco usage one of the biggest public healthy crises the world faces. Accumulating evidence suggests that smokers are more susceptible to bacterial or viral infection and exhibit greater severity of these infections [45,46]. There have also been limited accounts of cigarette smoking increasing severity of COVID-19 infection [46]. The millions of smokers worldwide may be especially vulnerable to COVID-19.

However, more concerning than tobacco usage has been the usage of e-cig. Although not nearly as popular as tobacco, e-cig usage has been gaining traction at alarming rates. Critically, the usage of e-cig has been increasing dramatically among teenagers. According to CDC data, more than 1.3 million high school students started using e-cig in one year alone (2017-2018), which is a 78% increase in usage (117% to 208%) [47]. From 2011 to 2018, the usage rate among high schoolers increased nearly 14 times (1.5% to 20.8%) [47]. Even among middle schoolers, usage rate increased over 8 times from 2011 to 2018 (0.6% to 4.9%) [47]. While the health effects of tobacco are well-known, much less is known about e-cig. In recent days, starting from late June, the surge in COVID-19 across the U.S. has been significantly attributed to increased incidence amongst the younger segment of the population. Given the prevalence of e-cig vaping in the young population, significant attention must be paid to how e-cig use may be related to COVID-19 incidence and severity.
Originally marketed as a safer alternative to traditional cigarettes, alarming health risks of e-cig have been slowly revealed. E-cig could be cytotoxic to both endothelial and epithelial cells and may decrease immune functions [48]. However, study of e-cig is complicated by the presence of nicotine and flavorings. Not all e-cig has nicotine and flavoring, but almost all brands have one or the other. These components can be significantly more cytotoxic than the base ingredients of e-cig, which is propylene glycol (PG) and vegetable glycerin (VG). While nicotine is known to be cytotoxic, we have previously reported that e-cig without nicotine can also induce DNA double strand breaks in cells [49].

In this study, we compared differences in the activation of key molecular pathways related to COVID-19 in tobacco and e-cig users. Specifically, we examined one cohort of e-cig users who only smoked e-cig without nicotine and without flavorings and another cohort of e-cig users who smoked e-cig with nicotine and with any flavorings. We found that tobacco use increases ACE2 expression, which corroborates the results of other studies [50]. However, e-cig use in any case did not increase ACE2 expression, which has not been reported in the literature. One recent study exposing mice to nicotine-containing e-cig for 1 month has found induction of ACE2 after exposure to nicotine-containing e-cig [51]. In our dataset, humans were also exposed to nicotine-containing e-cig for at least 1 month, suggesting that the in vivo results may not replicate physiological exposure.

We also found that tobacco use and use of nicotine/flavor-containing e-cig led to significant cytokine dysregulation and potential inflammasome activation. However, non-flavored and non-nicotine-containing e-cig use does not lead to either. While it has been reported that there is only limited inflammation in users of e-cig without nicotine and flavors [24], no study has compared gene expression changes of this group of e-cig users to users of nicotine/flavor-containing e-cig. One study also demonstrated inflammasome activation among e-cig users but did not take into account effects of nicotine and flavors [52].

Several limitations exist in our study that should be addressed in future studies. First, for the tobacco dataset, current smokers were only compared to former smokers, not never smokers. Second, for the e-cig dataset with flavor/nicotine-containing e-cig, only former smokers, not never smokers, were participants. However, since both the experimental and control group are composed of former smokers, the effect of smoking should not affect the statistical validity of our comparisons. Third, in the e-cig studies, participants were only exposed to e-cig for at least 1 month, while certain effects of e-cig may be expected to develop only after chronic exposure. Nonetheless, given that we observed cytokine/inflammasome dysregulations already given the relative short duration of exposure, we may expect chronic exposure to lead to even more dysregulation.

In conclusion, our study has demonstrated that tobacco and flavored or nicotine-containing e-cig use could both lead to increased inflammatory response, but only tobacco upregulates ACE2. Inflammation and ACE2 upregulation may increase susceptibility to COVID-19. While further experiments and epidemiology data are needed to confirm our results, we believe that our study is a critical early step into evaluating the implications of using tobacco and e-cig during the COVID-19 pandemic.

4. Materials and Methods

4.1. Datasets of Gene Expression from E-cig and tobacco samples

Bronchial epithelial cell sequencing data from e-cig and non e-cig users were obtained from GSE138326 (n=15 e-cig, 15 non-e-cig), provided by Song et al. [24], and GSE12073 (n=15 e-cig, 21 no e-cig), provide by Corbett et. al. [25]. In the Song et. al. dataset, 30 healthy subjects (21-30 years old) with no prior history of e-cig or tobacco use were randomly assigned to a e-cig vaping group or control group. In the e-cig vaping group, participants used the device twice a day at 20 puffs per session for exactly 4 weeks. E-cig was composed of 50% PG and 50% VG, with no nicotine or flavor. In the Corbett et. al. dataset, patients were aged 18-55 years old and were all former cigarette smokers, defined as having been tobacco-abstinent for over 3 months and have smoked at least 5 cigarettes for 2 years or
more at some point of their lives. 15 subjects are former tobacco smokers who have used nicotine-containing e-cig of any brand or flavoring for at least 6 days a week and at least 1 month. 25 subjects are former tobacco smokers who have not used any nicotine-replacement device. Bronchoscopies were performed on all subjects for both studies, and bronchial brushings from the epithelium were profiled by microarray. RNA sequencing data for current and former tobacco smokers were obtained from adjacent normal samples of 49 lung squamous cell carcinoma (LUSC) patients from The Cancer Genome Atlas (TCGA).

4.2. Differential expression analysis

Differential expression was assessed between LUSC samples from current smokers and former smokers using the Kruskal-Wallis test (p<0.05). Microarray data from the e-cig datasets were analyzed using both the GEO2R software, which employs the limma (Linear Models for Microarray Analysis) R package, and the Kruskal-Wallis test (p<0.05). Non-smoking control vs. e-cig samples and samples from former smokers vs. former smokers who smoke e-cig were the comparisons made for the two studies.

4.3. Inference of immune cell infiltration populations using Cibersort

The Cibersort algorithm was be used to deconvolute microarray and RNA-sequencing data to estimate the infiltration levels of 22 immune cell types [26]. The immune cell types examined include, naive B-cells, memory B-cells, plasma cells, CD8 T-cells, CD4 naive T-cells, CD4 memory resting T-cells, CD4 memory activated T-cells, follicular helper T-cells, regulatory T-cells, gamma-delta T-cells, resting NK cells, activated NK cells, monocytes, M0-M2 macrophages, resting dendritic cells, activated dendritic cells, resting mast cells, activated mast cells, eosinophils, and neutrophils.

4.4. Correlation of smoking status/e-cig vaping status to pathways or signatures using GSEA

GSEA was used to determine the correlation to biological pathways or signatures for the same comparisons described in Section 4.1 [53]. A categorical phenotype file was used, with e-cig users, tobacco users, or control as labels. Gene sets were obtained from the Molecular Signatures Database (MSigDB) [54]. Canonical pathways (C2) and immunological signatures (C7) were correlated with vaping/smoking status (p<0.05).

4.5. Selection of cytokine and cytokine-related genes for analysis

Cytokines and cytokine-related included chemokines, chemokine receptors, interleukins, interleukin receptors, interferons, tumor necrosis factors (TNFs), and TGFβ family members.

4.6. Selection of inflammasome-related genes for analysis

Both genes for proteins that constitute the inflammasome complex and genes that regulate the expression of these inflammasome components are included in our analyses. The former includes inflammasome sensor proteins, such as NLRP family proteins, AIM2, and NAIP; adaptor proteins, such as ASC (PYCARD); or effectors, including caspase proteins [40]. The latter includes NF-kB, IKK, MAPK3, and TAK1 [55].

Author Contributions: Conceptualization, W.M.O.; methodology, W.M.O.; software, N/A; validation, A.C.L., J.C., and W.T.L.; formal analysis, A.C.L., J.C., C.C. and W.T.L; investigation, A.C.L., J.C., C.C., and W.T.L.; resources, W.M.O.; data curation, N/A; writing—original draft preparation, A.C.L., J.C., and W.T.L.; writing—review and editing, A.C.L., J.C., W.T.L., E.Y.C., and J.W.R.; visualization, A.C.L., J.C., and W.T.L.; supervision, W.M.O.; project administration, W.M.O.; funding acquisition, W.M.O. All authors have read and agreed to the published version of the manuscript.
Funding: This research was funded by the University of California, Office of the President/Tobacco-Related Disease Research Program Emergency COVID-19 Research Seed Funding Grant (Grant number: R00RG2369) to W.M.O. and the University of California, San Diego Academic Senate Grant (Grant number: RG096651) to W.M.O.

Acknowledgments: None.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

- PG: propylene glycol
- VG: vegetable glycerin
- LUSC: lung squamous cell carcinoma
- MSigDB: Molecular Signatures Database
- TNF: tumor necrosis factor
- limma: Linear Models for Microarray Analysis
- Treg: Regulatory T cells
- PBMCs: Peripheral Blood Mononuclear Cells
- TCGA: The Cancer Genome Atlas

References

1. Wu, Z.; McGooGAN, J.M. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020, 10.1001/jama.2020.2648, doi:10.1001/jama.2020.2648.

2. Vardavas, C.I.; Nikitara, K. COVID-19 and smoking: A systematic review of the evidence. Tob Induc Dis 2020, 18, 20. doi:10.18332/tid/119324.

3. Zhao, Q.; Meng, M.; Kumar, R.; Wu, Y.; Huang, J.; Lian, N.; Deng, Y.; Lin, S. The impact of COPD and smoking history on the severity of Covid-19: A systematic review and meta-analysis. J Med Virol 2020, 10.1002/jmv.25889, doi:10.1002/jmv.25889.

4. Laniado-Laborin, R. Smoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21st century. Int J Environ Res Public Health 2009, 6, 209-224, doi:10.3390/ijerph6010209.

5. Berlin, I.; Thomas, D.; Le Faou, A.L.; Cornuz, J. COVID-19 and smoking. Nicotine Tob Res 2020, 10.1093/ntr/ntaa039, doi:10.1093/ntr/ntaa039.

6. Farsalinos, K.; Barbouni, A.; Niaura, R. Smoking, vaping and hospitalization for COVID-19. Qeios 2020, https://doi.org/10.32388/26908A8, doi:https://doi.org/10.32388/26908A8.

7. Lippi, G.; Henry, B.M. Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). Eur J Intern Med 2020, 75, 107-108, doi:10.1016/j.ejim.2020.03.014.

8. Changeux, J.-P.; Amoura, Z.; Rey, F.; Miyara, M. A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications. Qeios 2020, 10.32388/FXQSB, doi:10.32388/FXQSB.

9. Nilsson, P.; Mallet, V. France limits nicotine sales after coronavirus study. Financial Times 2020.

10. Bao, W.; Xu, G.; Lu, J.; Smetalselaar, L.G.; Wallaer, R.B. Changes in Electronic Cigarette Use Among Adults in the United States, 2014-2016. JAMA 2018, 319, 2039-2041, doi:10.1001/jama.2018.4658.

11. McAllinden, K.D.; Eapen, M.S.; Lu, W.; Chia, C.; Haug, G.; Sohal, S.S. COVID-19 and vaping: risk for increased susceptibility to SARS-CoV-2 infection? Eur Respir J 2020, 10.1183/13993003.01645-2020, doi:10.1183/13993003.01645-2020.
12. Reinkovaite, V.; Rodriguez, I.E.; Karoor, V.; Rau, A.; Trinh, B.B.; Deleyiannis, F.W.;
Tanasevic-Stewart, L. The effects of electronic cigarette vapour on the lung: direct comparison to
13. tobacco smoke. *Eur Respir J* 2018, 51, doi:10.1183/13993003.01661-2017.
14. Muthumalage, T.; Lamb, T.; Friedman, M.R.; Rahman, I. E-cigarette flavored pods induce
15. inflammation, epithelial barrier dysfunction, and DNA damage in lung epithelial cells and monocytes.
*Sci Rep* 2019, 9, 19035, doi:10.1038/s41598-019-51643-6.
16. Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichen, S.; Schiergens, T.S.;
17. Herrler, G.; Wu, N.-H.; Nitsche, A., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and
18. Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 2020, 181, 271-280.e278,
19. doi:https://doi.org/10.1016/j.cell.2020.02.052.
20. Smith, J.C.; Sheltzer, J.M. Cigarette smoke triggers the expansion of a subpopulation of respiratory
21. epithelial cells that express the SARS-CoV-2 receptor ACE2. *bioRxiv* 2020, 10.1101/2020.03.28.013672,
22. 2020.03.28.013672, doi:10.1101/2020.03.28.013672.
23. Leung, J.M.; Yang, C.X.; Tam, A.; Shaipanich, T.; Hackett, T.L.; Singhera, G.K.; Dorscheid, D.R.; Sin,
24. D.D. ACE-2 Expression in the Small Airway Epithelia of Smokers and COPD Patients: Implications for
25. COVID-19. *Eur Respir J* 2020, 10.1183/13993003.00688-2020, doi:10.1183/13993003.00688-2020.
26. Cai, G.; Bosse, Y.; Xiao, F.; Kheradmand, F.; Amos, C.I. Tobacco Smoking Increases the Lung Gene
27. Expression of ACE2, the Receptor of SARS-CoV-2. *Am J Respir Crit Care Med* 2020,
28. 10.1164/rcrm.202003-0693LE, doi:10.1164/rcrm.202003-0693LE.
29. Mehta, P.; McAuley, D.F.; Brown, M.; Sanchez, E.; Tattersall, R.S.; Manson, JJ.; Hlh Across Speciality
30. Collaboration, U.K. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*
31. 2020, 395, 1033-1034, doi:10.1016/S0140-6736(20)30628-0.
32. Vaninov, N. In the eye of the COVID-19 cytokine storm. *Nat Rev Immunol* 2020,
33. 10.1038/s41577-020-0305-6, doi:10.1038/s41577-020-0305-6.
34. Lee, J.; Taneja, V.; Vassallo, R. Cigarette Smoking and Inflammation: Cellular and Molecular
35. Mechanisms. *J Dent Res* 2012, 91, 142-149, doi:10.1177/0022034511421200.
36. Scott, A.; Lugg, S.T.; Aldridge, K.; Lewis, K.E.; Bowden, A.; Mahids, R.Y.; Grudzinska, F.S.; Dosanjh,
37. D.; Parekh, D.; Foronjy, R., et al. Pro-inflammatory effects of e-cigarette vapour condensate on human
38. alveolar macrophages. *Thorax* 2018, 73, 1161-1169, doi:10.1136/thoraxjnl-2018-211663.
39. Reidel, B.; Radicici, G.; Clapp, P.W.; Ford, A.A.; Abdelwahab, S.; Rebuli, M.E.; Haridass, P.; Alexis,
40. N.E.; Jaspers, J.; Kesimer, M. E-Cigarette Use Causes a Unique Innate Immune Response in the Lung,
41. Involving Increased Neutrophil Activation and Altered Mucin Secretion. *Am J Respir Crit Care Med*
42. 2018, 197, 492-501, doi:10.1164/rcrm.2017-1590OC.
43. Song, M.A.; Reisinger, S.A.; Freudenheim, J.L.; Brasky, T.M.; Mathé, E.A.; McElroy, J.P.; Nickerson,
44. Q.A.; Weng, D.Y.; Wewers, M.D.; Shields, P.G. Effects of Electronic Cigarette Constituents on the
45. Human Lung: A Pilot Clinical Trial. *Cancer Prev Res (Phila)* 2020, 13, 145-152,
doi:10.1158/1940-6207.CAPR-19-0400.
25. Corbett, S.E.; Nitzberg, M.; Moses, E.; Kleerup, E.; Wang, T.; Perdomo, C.; Perdomo, C.; Liu, G.; Xiao, X.; Liu, H., et al. Gene Expression Alterations in the Bronchial Epithelium of e-Cigarette Users. *Chest* 2019, 156, 764-773, doi:10.1016/j.chest.2019.05.022.

26. Chen, B.; Khodadoust, M.S.; Liu, C.L.; Newman, A.M.; Alizadeh, A.A. Profiling Tumor Infiltrating Immune Cells with CIBERSORT. *Methods Mol Biol* 2018, 1711, 243-259, doi:10.1007/978-1-4939-7493-1_12.

27. Dutta, A.; Miaw, S.C.; Yu, J.S.; Chen, T.C.; Lin, C.Y.; Lin, Y.C.; Chang, C.S.; He, Y.C.; Chuang, S.H.; Yen, M.I., et al. Altered T-bet dominance in IFN-gamma-decoupled CD4+ T cells with attenuated cytokine storm and preserved memory in influenza. *J Immunol* 2013, 190, 4205-4214, doi:10.4049/jimmunol.1202434.

28. Gogishvili, T.; Langenhorst, D.; Luhrder, F.; Elias, F.; Elfellin, K.; Dennehy, K.M.; Gold, R.; Hunig, T. Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice. *PLoS One* 2009, 4, e4643, doi:10.1371/journal.pone.0004643.

29. Brandsma, C.A.; Hylkema, M.N.; Geerlings, M.; van Giffin, W.H.; Postma, D.S.; Timens, W.; Kestjens, H.A. Increased levels of (class switched) memory B cells in peripheral blood of current smokers. *Respir Res* 2009, 10, 108, doi:10.1186/1465-9921-10-108.

30. Ng, L.F.; Hibberd, M.L.; Ooi, E.E.; Tang, K.F.; Neo, S.Y.; Tan, J.; Murthy, K.R.; Vega, V.B.; Chia, J.M.; Liu, E.T., et al. A human in vitro model system for investigating genome-wide host responses to SARS coronavirus infection. *BMC Infect Dis* 2004, 4, 34, doi:10.1186/1471-2334-4-34.

31. Conti, P.; Ronconi, G.; Caraffa, A.; Gallenga, C.E.; Ross, R.; Frydach, I.; Kritas, S.K. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. *J Biol Regul Homeost Agents* 2020, 34, doi:10.23812/CONTE.

32. Zhou, Z.; Ren, L.; Zhang, L.; Zhong, J.; Xiao, Y.; Jia, Z.; Guo, L.; Yang, J.; Wang, C.; Jiang, S., et al. Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients. *Cell Host Microbe* 2020, 27, 883-890 e882, doi:10.1016/j.chom.2020.04.017.

33. Donnelly, S.C.; Strierter, R.M.; Kunkel, S.L.; Walz, A.; Robertson, C.R.; Carter, D.C.; Grant, I.S.; Pollok, A.J.; Haslett, C. Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups. *Lancet* 1993, 341, 643-647, doi:10.1016/0140-6736(93)90416-e.

34. Miller, E.J.; Cohen, A.B.; Nagao, S.; Griffith, D.; Maunder, R.J.; Martin, T.R.; Weiner-Kronish, J.P.; Sticherling, M.; Christophers, E.; Matthay, M.A. Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality. *Am Rev Respir Dis* 1992, 146, 427-432, doi:10.1164/ajrccm/146.2.427.

35. Groeneveld, A.B.; Rajmakers, P.G.; Hack, C.E.; Thijs, L.G. Interleukin 8-related neutrophil elastase and the severity of the adult respiratory distress syndrome. *Cytokine* 1995, 7, 746-752, doi:10.1006/cyto.1995.0089.

36. Miller, E.J.; Cohen, A.B.; Matthay, M.A. Increased interleukin-8 concentrations in the pulmonary edema fluid of patients with acute respiratory distress syndrome from sepsis. *Crit Care Med* 1996, 24, 1448-1454, doi:10.1097/00003246-199609000-00004.

37. Trifilo, M.J.; Bergmann, C.C.; Kuziel, W.A.; Lane, T.E. CC chemokine ligand 3 (CCL3) regulates CD8(+) T-cell effector function and migration following viral infection. *J Virol* 2003, 77, 4004-4014, doi:10.1128/jvi.77.7.4004-4014.2003.
38. Tyner, J.W.; Uchida, O.; Kajiwara, N.; Kim, E.Y.; Patel, A.C.; O'Sullivan, M.P.; Walter, M.J.; Schwendener, R.A.; Cook, D.N.; Danoff, T.M., et al. CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection. Nat Med 2005, 11, 1180-1187, doi:10.1038/nm1303.

39. Tekamp-Olson, P.; Gallegos, C.; Bauer, D.; McClain, J.; Sherry, B.; Fabre, M.; van Deventer, S.; Cerami, A. Cloning and characterization of cDNAs for murine macrophage inflammatory protein 2 and its human homologues. J Exp Med 1990, 172, 911-919, doi:10.1084/jem.172.3.911.

40. Lu, A.; Wu, H. Structural mechanisms of inflammasome assembly. FEBS J 2015, 282, 435-444, doi:10.1111/febs.13133.

41. Boro, M.; Balaji, K.N. CXCL1 and CXCL12 Regulate NLRP3 Inflammasome Activation via G-Protein-Coupled Receptor CXCR2. J Immunol 2017, 199, 1660-1671, doi:10.4049/jimmunol.1700129.

42. Rajamaki, K.; Mayranpaa, M.I.; Risco, A.; Tuimala, J.; Nurmi, K.; Cuende, A.; Eklund, K.K.; Oorni, K.; Kovanen, P.T. p38delta MAPK: A Novel Regulator of NLRP3 Inflammasome Activation With Increased Expression in Coronary Atherogenesis. Arterioscler Thromb Vasc Biol 2016, 36, 1937-1946, doi:10.1161/ATVBAHA.115.30512.

43. Heu, L.C.; Ali, S.R.; McGillivray, S.; Tseng, P.H.; Mariathanas, S.; Humke, E.W.; Eckmann, L.; Powell, J.J.; Nizet, V.; Dixit, V.M., et al. A NOD2-NALP1 complex mediates caspase-1-dependent IL-1beta secretion in response to Bacillus anthracis infection and muramyl dipeptide. Proc Natl Acad Sci U S A 2008, 105, 7803-7808, doi:10.1073/pnas.080276108.

44. QuickStats: Percentage of Adults Aged 18-24 Years Who Currently Smoke Cigarettes* or Who Currently Use Electronic Cigarettes, (dagger) by Year - National Health Interview Survey, United States, 2014-2018 (section sign). MMWR Morb Mortal Wkly Rep 2019, 68, 870, doi:10.15585/mmwr.mm6839a6.

45. Regaikar, J.; Demuth, D.R.; Scott, D.A. Tobacco use increases susceptibility to bacterial infection. Tob Induc Dis 2008, 4, 12, doi:10.1186/1617-9625-4-12.

46. van Zyl-Smit, R.N.; Richards, G.; Leone, F.T. Tobacco smoking and COVID-19 infection. Lancet Respir Med 2020, 10.1016/S2213-2600(20)30293-3, doi:10.1016/S2213-2600(20)30293-3.

47. Cullen, K.A.; Ambrose, B.K.; Gentzke, A.S.; Apelberg, B.J.; Jamal, A.; King, B.A. Notes from the Field: Use of Electronic Cigarettes and Any Tobacco Product Among Middle and High School Students - United States, 2011-2018. MMWR Morb Mortal Wkly Rep 2018, 67, 1276-1277, doi:10.15585/mmwr.mm6745a5.

48. Chaffee, B.W. Electronic Cigarettes: Trends, Health Effects and Advising Patients Amid Uncertainty. J Calif Dent Assoc 2019, 47, 85-92.

49. Yu, V.; Rahimy, M.; Korrapati, A.; Xuan, Y.; Zou, A.E.; Krishnan, A.R.; Tsui, T.; Aguilera, J.A.; Advani, S.; Crotty Alexander, L.E., et al. Electronic cigarettes induce DNA strand breaks and cell death independently of nicotine in cell lines. Oral Oncol 2016, 52, 58-65, doi:10.1016/j.joraloncology.2015.10.018.

50. Cai, G.; Bosse, Y.; Xiao, F.; Kheradmand, F.; Amos, C.I. Tobacco Smoking Increases the Lung Gene Expression of ACE2, the Receptor of SARS-CoV-2. Am J Respir Crit Care Med 2020, 201, 1557-1559, doi:10.1164/rcrm.202003-0693LE.

51. Wang, Q.; Sundar, I.K.; Li, D.; Lucas, J.H.; Muthumalage, T.; McDonough, S.R.; Rahman, I. E-cigarette-induced pulmonary inflammation and dysregulated repair are mediated by nAChR alpha 7.
No natural text is provided.
Current Smokers vs Former Smokers that have quit for less than 15 years

Current Smokers vs Former Smokers that have quit for more than 15 years

Current Smokers vs All Former Smokers (age-matched)

**A**

No Flavor, No Nicotine: Control VS E-cig

Flavor/Nicotine-containing: Control VS E-cig

**B**

Current vs Former Smokers

Control vs E-cig (No Flavor, No Nicotine)

Control vs E-cig (Flavor/Nicotine-containing)

**C**

**D**

**E**
Current Smokers vs Former Smokers that have quit for less than 15 years

**A**

Current vs Former Smokers (age-matched)

Fold Change

-4 -2 0 2 4 6 8

Genes

CCL20 CXCL8 CXCL4 CXCL8 CXCL4 CXCL10 CX3CR1 IL1B IL17D TNFSF12 TNFSF9 TNFSF14 CXCL17 IL10RB IL17RD TGFB2 TGFBR2 IL10RB.AS1

* p < 0.05
** p < 0.01
*** p < 0.005

Former Smokers: Control VS E-cig
Never Smokers: Control vs E-cig

\* p < 0.05
\** p < 0.01
\*** p < 0.005

**B**

Never Smokers: Control vs E-cig (No Flavor/nicotine)

Fold Change

IFNA8

CCL20 CXCL8 CXCL1 CXCL2 CXCL3 CXCL8 TNFSF9 TNFRSF14 TGFB2 IL10RB AS1

* p < 0.05
** p < 0.01
*** p < 0.005

**C**

Former Smokers: Control VS Ecig (Flavor/nicotine-containing)

Fold Change

CCL5 CCL1 IL17F CXCL3 IL20R IL22RA1 IL18

**p < 0.05
** p < 0.01
*** p < 0.005

**D**

Current vs Former Smokers that have quit for less than 15 years

Fold Change

Row Z-Score

CCL20 CXCL1 CXCL2 TNFSF12 TNFSF9 IL17RC IL17RD

**E**

Current vs Former Smokers that have quit for more than 15 years

Fold Change

Row Z-Score

CCL20 CXCL1 CXCL2 CXCL3 CXCL8 TNFSF9 TNFRSF14 TGFB2 IL17RD

-1.5 -1 -0.5 0 0.5 1 1.5

Genes

CCL5 CCL1 IL17F CXCL3 IL20R IL22RA1 IL18

* p < 0.05
** p < 0.01
*** p < 0.005

This version posted July 13, 2020. doi: 10.1101/2020.07.13.198630
